- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04366154
Impact of the COVID-19 Infectious Epidemic on the Management of Oncology and Onco-hematology Patients and on the Psychological Consequences for Patients and Caregivers (COVIPACT)
This original study will assess the impact of the coronavirus health crisis on the management of patients undergoing medical treatment for cancer, in particularly on the modification of the hospital organization. It will also provide a record of the progress of patients who will have been treated during the epidemic period and infected by the virus.
We will also assess the psychological impact of the pandemic in patients but also in caregivers
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
-
Caen, France
- Centre Francois Baclesse
-
Rouen, France
- Centre Henri Becquerel
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
For Patients:
- Adult patient, treated for a solid or hematological tumor
- will be treated ou actually treated by oncological treatment carried out at the hospital in day unit of the participating centers: treatment initiated before or during the pandemic with COVID-19
For the Caregivers:
- Medical oncologist, hematologist, intern, nurse and caregiver in day unit of hospital
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Aidants
|
delivery of questionnaires on perceived stress, post-traumatic stress, sleep disorders, quality of life, cognitive complaint
|
|
Les patients
|
delivery of questionnaires on perceived stress, post-traumatic stress, sleep disorders, quality of life, cognitive complaint
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
To assess the impact of the COVID-19 pandemic on the modifications of treatments administered in hospital (day units) to patients with cancer or malignant hemopathy
Délai: up to 6 months
|
Proportion of patients with modification of the treatments administered
|
up to 6 months
|
|
To assess the impact of the COVID-19 pandemic on the change in the rate of treatment administration in hospital (day units) to patients with cancer or malignant hemopathy
Délai: up to 6 months
|
Proportion of patients with change in the rate of treatment administration
|
up to 6 months
|
|
To assess the impact of the COVID-19 pandemic on the number of cures administeredin hospital (day units) to patients with cancer or malignant hemopathy
Délai: up to 6 months
|
Proportion of patients with change in the number of cures administered
|
up to 6 months
|
|
To assess the impact of the COVID-19 pandemic on change of modality of administration in hospital (day units) to patients with cancer or malignant hemopathy
Délai: up to 6 months
|
Proportion of patients with change of modality of administration (home administration to replace day hospital administration, teleconsultation uses)
|
up to 6 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Evaluate the perceived stress on cancer patients treated in unit day of hospital
Délai: up to 12 months
|
Score of questionnaires of Perceived Stress Scale [0-40 points]
|
up to 12 months
|
|
Evaluate the post-traumatic stress on cancer patients treated in unit day of hospital
Délai: up to 12 months
|
Score of questionnaires of Impact of Event Scale-Revised [0-88 points]
|
up to 12 months
|
|
Evaluate the sleep disorders on cancer patients treated in unit day of hospital
Délai: up to 12 months
|
Score of questionnaires of sleep disorders (ISI scale, 0-28 points)
|
up to 12 months
|
|
Evaluate the quality of life on cancer patients treated in unit day of hospital
Délai: up to 12 months
|
Score of questionnaires of quality of life (FACT-G scale)
|
up to 12 months
|
|
Evaluate the cognitive complaints on cancer patients treated in unit day of hospital
Délai: up to 12 months
|
Score of questionnaires of cognitive complaints (Fact-Cog scales; 0-148 points)
|
up to 12 months
|
|
Evaluate the perceived stress on caregivers (perceived stress, post-traumatic stress, burnout, feeling of personal effectiveness)
Délai: up to 12 months
|
Score of questionnaires of Perceived Stress Scale [0-40 points]
|
up to 12 months
|
|
Evaluate the post-traumatic stress on caregivers (perceived stress, post-traumatic stress, burnout, feeling of personal effectiveness)
Délai: up to 12 months
|
Score of questionnaires of Impact of Event Scale-Revised [0-88 points]
|
up to 12 months
|
|
Evaluate the burnout on caregivers (perceived stress, post-traumatic stress, burnout, feeling of personal effectiveness)
Délai: up to 12 months
|
Score of questionnaires of burnout ((Maslach Burn Out Inventory scale, 0-132 points)
|
up to 12 months
|
|
Evaluate the feeling of personal effectiveness on caregivers (perceived stress, post-traumatic stress, burnout, feeling of personal effectiveness)
Délai: up to 12 months
|
Score of questionnaires of feeling of personal effectiveness (0-30 points)
|
up to 12 months
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2020-A00879-30
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur COVID-19 [feminine]
-
PfizerActif, ne recrute pasCOVID-19 [feminine] | Maladie à coronavirus 2019 (COVID-19) | Infection par covid-19 | Vaccins contre le covid-19 | Infection par le SRAS-CoV-2, COVID19 | Vaccination COVID-19 | Infection par le SRAS-CoV-2, COVID-19 | COVID-19 (maladie à coronavirus 2019) | COVID-19 Infection par le SRAS-CoV-2États-Unis
-
Shanghai Public Health Clinical CenterPas encore de recrutement
-
Duke UniversityNational Institute on Minority Health and Health Disparities (NIMHD)Complété
-
Eggensberger OHGBavarian Health and Food Safety Authority (LGL)RecrutementÉtat post-COVID-19 | Après COVID-19 | Syndrome post-COVID-19 | Syndrome long du COVID-19 | État post-COVID-19 (PCC)Allemagne
-
Lawson Research Institute of St. Joseph'sCanadian Institutes of Health Research (CIHR); Western University, CanadaRecrutementFatigue | Syndrome post-COVID-19 | État post-COVID-19 | Syndrome post-COVID | Longue COVID-19 | Long-COVID | État post-COVIDCanada
-
PfizerRecrutementMaladies des voies respiratoires | COVID-19 [feminine] | Pneumonie | Maladies pulmonaires | Maladie du coronavirus 2019 | Maladie à coronavirus 2019 (COVID-19) | Infection par covid-19 | Infections des voies respiratoires supérieures | Infection des voies respiratoires | COVID-19 (maladie à coronavirus... et d'autres conditionsBelgique
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkPas encore de recrutementSyndrome post-COVID-19 | Longue COVID | Longue Covid19 | État post-COVID-19 | Syndrome post-COVID | Condition post-COVID-19, non précisée | État post-COVIDPays-Bas
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlComplétéSéquelles post-aiguës de la COVID-19 | État post-COVID-19 | Long-COVID | Syndrome chronique du COVID-19Italie
-
Indonesia UniversityRecrutementSyndrome post-COVID-19 | Longue COVID | État post-COVID-19 | Syndrome post-COVID | Longue COVID-19Indonésie
-
ModeX Therapeutics, An OPKO Health CompanyRecrutementCOVID 19 | COVID-19 (Prévention)États-Unis